| Mr Arif A Chowdhury, MD | |
|
34503 9th Ave S Ste 230, Federal Way, WA 98003-8726 | |
| (253) 838-3103 | |
| (360) 782-3115 |
| Full Name | Mr Arif A Chowdhury |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 45 Years |
| Location | 34503 9th Ave S Ste 230, Federal Way, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225055023 | NPI | - | NPPES |
| 2068052 | Medicaid | WA |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Denali Healthcare Specialists Llc | 8820359458 | 4 |
News Archive
Children and youth born in Canada are at higher risk of unintentional injury from guns compared with immigrant children and youth, although certain subgroups of immigrants and refugees are at higher risk of assault-related injury, found a study published http://www.cmaj.ca/site/press/cmaj.160850.pdf in CMAJ.
A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.
Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board ("DSMB") recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer is being discontinued.
› Verified 7 days ago
| Entity Name | Denali Healthcare Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851829782 PECOS PAC ID: 8820359458 Enrollment ID: O20180328003017 |
News Archive
Children and youth born in Canada are at higher risk of unintentional injury from guns compared with immigrant children and youth, although certain subgroups of immigrants and refugees are at higher risk of assault-related injury, found a study published http://www.cmaj.ca/site/press/cmaj.160850.pdf in CMAJ.
A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.
Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board ("DSMB") recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer is being discontinued.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Arif A Chowdhury, MD 34503 9th Ave S Ste 230, Federal Way, WA 98003-8726 Ph: (253) 838-3103 | Mr Arif A Chowdhury, MD 34503 9th Ave S Ste 230, Federal Way, WA 98003-8726 Ph: (253) 838-3103 |
News Archive
Children and youth born in Canada are at higher risk of unintentional injury from guns compared with immigrant children and youth, although certain subgroups of immigrants and refugees are at higher risk of assault-related injury, found a study published http://www.cmaj.ca/site/press/cmaj.160850.pdf in CMAJ.
A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.
Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board ("DSMB") recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer is being discontinued.
› Verified 7 days ago
Jonathan Dehaan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 33501 1st Way S, Federal Way, WA 98003 Phone: 253-838-2400 | |
Ms. Marsha Lynn Cain, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 33516 Ninth Ave So, Bldg #7, Federal Way, WA 98003 Phone: 253-952-4779 Fax: 253-661-8112 | |
Edward Tay, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 301 S 320th St, Federal Way, WA 98003 Phone: 253-874-7958 | |
John S Wendt, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 34503 9th Ave S, Suite 230, Federal Way, WA 98003 Phone: 253-838-3103 Fax: 253-838-7134 | |
Dr. James Gary Trantham, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 402 S 333rd St, Federal Way, WA 98003 Phone: 253-945-0210 | |
Kate Onorato Bedrin, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 33501 1st Way S, Federal Way, WA 98003 Phone: 206-341-1900 |